natgillin/translations-raw huggingface dataset:
n represents an integer of 0, 1, 2, 3, 4 or 5; or a stereoisomer, a tautomer, an N-oxide, a hydrate, a solvate, or a salt thereof, or a mixture of same. 
C,-Cs-alkil-, C,-Cs-haloalkil-; n predstavlja cijeli broj od 0, 1, 2, 3, 4 1li 5; ili stereoizomer, tautomer, N-oksid, hidrat, solvat, ili njegova sol, ili smjesa istih.
The process according to any one of claims 5 to 25, characterized in that the solids concentration of material in the form of an aqueous suspension to be ground in grinding step d) is from 10 to 82 % (by dry weight of calcium carbonate material), preferably from 50 to 81 %, most preferably from 60 to 80 %, and especially preferably between 65% and 72%. 
Postupak u skladu s bilo kojim od patentnih zahtjeva 3 do 20, karakteriziran na način da koncentracija krutog materijala u obliku vodene otopine koju treba usitniti u koraku mljevenja d) iznosi od 10 do 82 % (prema suhoj težini materijala kalcijevog karbonata), poželjnije od 50 do 81 %, najpoželjnije od 60 do 80 %, a posebno poželjno između 65% i 72%.
In another embodiment, the monomers comprise Formula (Va): 
Spoj sukladno zahtjevu 1, naznačeno time, da spoj ima Formulu (IIb):
A compound represented by the formula (I) or a pharmaceutically acceptable salt thereof: wherein R1 represents OR, NRR' which may form a ring or SR, in which R and R' independently represent a hydrogen atom, a linear, cyclic or branched alkyl group having 1 to 8 carbon atoms optionally substituted with one or a plurality of linear, cyclic or branched alkoxy groups having 1 to 8 carbon atoms, halogen atoms or hydroxyl groups, an aryl group optionally substituted with one or a plurality of linear, cyclic or branched alkyl groups having 1 to 8 carbon atoms, linear, cyclic or branched alkoxy groups having 1 to 8 carbon atoms or halogen atoms, or a heteroaryl group optionally substituted with one or a plurality of linear, cyclic or branched alkyl groups having 1 to 8 carbon atoms, a linear, cyclic or branched alkoxy groups having 1 to 8 carbon atoms or a halogen atom, 
Ru pri čemu R, predstavlja OR, NRR' koji može tvoriti prsten ili SR, u kojem R i R' neovisno predstavljaju vodikov atom, ravnu, cikličku ili razgranatu alkilnu skupinu koja ima 1 do 8 ugljikovih atoma po izboru supstituiranu s jednom ili više ravnih, cikličkih ili razgranatih alkoksi skupina koje imaju 1 do 8 ugljikovih atoma, halogene atome ili hidroksilne skupine, arilnu skupinu proizvoljno supstituiranu s jednom ili više ravnih, cikličkih ili razgranatih alkilnih skupina koje imaju 1 do 8 ugljikovih atoma, ravnih, cikličkih ili razgranatih alkoksi skupina koje imaju 1 do 8 ugljikovih atoma ili halogene atome, ili heteroarilnu skupinu po izboru supstituiranu s jednom ili više ravnih, cikličkih ili razgranatih alkilnih skupina koje imaju 1 do 8 ugljikovih atoma, ravnih, cikličkih ili razgranatih alkoksi skupina koje imaju 1 do 8 ugljikovih atoma ili halogeni atom, R, predstavlja vodikov atom, ili ravnu, cikličku ili razgranatu alkilnu skupinu koja ima 1 do 8 ugljikovih atoma, i
The use of claim 42 wherein the cancer is a solid tumor, a sarcoma, fibrosarcoma, osteoma, melanoma, retinoblastoma, a rhabdomyosarcoma, glioblastoma, neuroblastoma, teratocarcinoma, an hematopoietic malignancy, malignant ascites, Kaposi's sarcoma, Hodgkin's disease, lymphoma, myeloma, or leukemia. 
Spoj prema patentnom zahtjevu 39, naznačen time što je rak solidni tumor, sarkom, fibrosarkom, osteom, melanom, retinoblastom, rabdomiosarkom, glioblastom, neuroblastom, teratokarcinom, hematopocetski malignitet, maligni ascites, Kaposijev sarkom, Hodgkinova bolest, limfom, mijelom ili leukemija.
The polypeptide of any one of claims 1-2 wherein at least one of the soluble TNF-family cytokine domains, particularly at least one of the soluble TNF family cytokine domains (iii) and (v) is a soluble TRAIL domain with an N-terminal sequence which starts between amino acid GIn120 and Val122 of human TRAIL and wherein Arg121 may be replaced by a neutral amino acid, e.g. Ser or Gly. 
Polipeptid prema bilo kojem od zahtjeva 1-2 pri kojem je najmanje jedna od topljivih citokinskih domena iz TNF obitelji, naročito najmanje jedna topljiva citokinska domena TNF obitelji (iii) i (v), topljiva TRAIL domena s N-terminalnim slijedom koji počinje između amino kiseline Gln120 1 Val122 od humane TRAIL i pri čemu Arg121 može biti zamijenjena neutralnom aminokiselinom, primjerice Ser ili Gly.
The elimination rate of ST2087 remains of the same order of magnitude as that observed for the same molecule, after administration of ST1469. 
Stopa uklanjanja ST2087 ustaje istog reda veličine kao ona zabilježena za istu molekulu, nakon primjene ST1469.
According to one embodiment the salifiable alkaline or alkaline earth compound is an alkaline or alkaline earth oxide, an alkaline or alkaline earth hydroxide, an alkaline or alkaline earth alkoxide, an alkaline or alkaline earth methylcarbonate, an alkaline or alkaline earth hydroxycarbonate, an alkaline or alkaline earth bicarbonate, an alkaline or alkaline earth carbonate, or a mixtures thereof, preferably the salifiable alkaline or alkaline earth compound is an alkaline or alkaline earth carbonate being preferably selected from lithium carbonate, sodium carbonate, potassium carbonate, magnesium carbonate, calcium magnesium carbonate, calcium carbonate, or mixtures thereof, more preferably the salifiable alkaline or alkaline earth compound is calcium carbonate, and most preferably the salifiable alkaline or alkaline earth compound is a ground calcium carbonate, a precipitated calcium carbonate and/or a surface-treated calcium carbonate. 
Postupak prema bilo kojem od prethodnih zahtjeva, naznačen time da alkalijski ili zemno alkalijski spoj koji tvori sol je alkalijski ili zemno alkalijski oksid, alkalijski ili zemno alkalijski hidroksid, alkalijski ili zemno alkalijski alkoksid, alkalijski ili zemno alkalijski metilkarbonat, alkalijski ili zemno alkalijski hidroksikarbonat, alkalijski ili zemno alkalijski bikarbonat, alkalijski ili zemno alkalijski karbonat, ili njihove smjese, poželjno alkalijski ili zemno alkalijski spoj koji tvori sol je alkalijski ili zemno alkalijski karbonat koji je poželjno odabran od litijevog karbonata, natrijevog karbonata, kalijevog karbonata, kalcijevog karbonata, ili kalcijevog karbonata, ili njihovih smjesa, poželjnije alkalijski ili zemno alkalijski spoj koji tvori sol je kalcijev karbonat, te najpoželjnije alkalijski ili zemno alkalijski spoj koji tvori sol je mljeveni kalcijev karbonat, istaloženi kalcijev karbonat i/ili površinski obrađeni kalcijev karbonat.
The composition for the use according to claim 9, wherein said disease is selected from squamous cell carcinoma, leukemia, acute lymphocytic leukemia, acute lymphoblastic leukemia, B-cell lymphoma, T-cell lymphoma, Hodgkin's lymphoma, non-Hodgkin's lymphoma, hairy cell lymphoma, Burkitt's lymphoma, an acute or chronic myelogenous leukemia, promyelocytic leukemia, fibrosarcoma, neuroblastoma, glioma, astrocytoma, schwannomas, fibrosarcoma, rhabdomyosarcoma, osteosarcoma, melanoma, xeroderma pigmentosum, keratoacanthoma, seminoma, thyroid follicular cancer, teratocarcinoma, other carcinoma of the bladder, breast, colon, kidney, liver, lung, ovary, prostate, pancreas, stomach, cervix, thyroid or skin, other hematopoietic tumors of lymphoid lineage, other hematopoietic tumors of myeloid lineage, other tumors of mesenchymal origin, and other tumors of the central or peripheral nervous system. 
Oblik prema zahtjevu 42, gdje taj bolesnik boluje od raka, drugog proliferativnog poremećaja, infektivne bolesti ili imunog poremećaja. Oblik prema zahtjevu 43, gdje taj bolesnik boluje od karcinoma skvamoznih stanica, leukemije, akutne limfoticne leukemije, akutne limfoblastične leukemije, limfoma B-stanica, limfoma T-stanica, Hodgkinovog limfoma, ne-Hodgkinovog limfoma, limfoma dlakavih stanica, Burkettovog limfoma, akutnih ili kroničnih mijeloičnih leukemija, promijelocitne leukemije, fibrosarkoma, rabdomiosarkoma; melanoma, seminoma, teratokarcinoma, neuroblastoma, glioma, astrocitoma, schwannoma, osteosarkoma, kseroderme pigmentosum, keratoakantoma, raka folikula štitnjače, drugog karcinoma mjehura, dojke, kolona, bubrega, jetre, pluča, jajnika, prostate, gušterače, želuca, cerviksa, štitnjače ili kože, drugih hematopoetskih tumora limfoidne linije, drugih hematopoetskih tumira mijeloične linije, drugih tumora mezenhimskog porijekla, drugih tumora središnjeg ili perifernog živčanog sustava.
In another embodiment, the conditions effective to reduce residual organic compounds in the gaseous mixture comprise UV light at a wavelength of about 220 nm to about 254 nm. 
(1i) UV svjetlost kod valne duljine od 200 nm do 300 nm, poželjnije kod valne duljine od 220 nm do 254 nm.
The portable cooking and delivery system of clause 1 wherein the heating element of at least one of the ovens is an electric heating element. The portable cooking and delivery system of clause 1 wherein at least one of the ovens includes an ejector moveable between a retracted configuration and an expanded configuration, wherein movement of the ejector from the retracted configuration to the expanded configuration moves the contents of the oven out of the oven without the contents being touched by a human. 
Postupak prema zahtjevu 9, naznačen time, da najmanje jedan od štednjaka (210) obuhvaća uređaj za izbacivanje koji je pomičan između uvučene konfiguracije i rastegnute konfiguracije, te time, da nadalje obuhvaća sljedeće: pomicanje uređaja za izbacivanje (246) iz uvučene konfiguracije prema rastegnutoj konfiguraciji, u svrhu pomicanja sadržina štednjaka izvan štednjaka, bez doticaja ljudskih ruku sa sadržajem.
Benzoic acid or a benzoic acid salt for use in a method of mitigating one or more symptoms of a neuropsychiatric disorder, wherein the benzoic acid salt is selected from the group consisting of sodium benzoate, potassium benzoate, calcium benzoate, and lithium benzoate, wherein the amount of the benzoic acid or benzoic acid salt is sufficient to mitigate one or more of said symptoms and ranges from about 5 mg to 500 g; and 
Benzojeva kiselina ili sol benzojeve kiseline za uporabu u metodi ublažavanja jednog ili više simptoma shizofrenije pri čemu se sol benzojeve kiseline bira iz skupine koja se sastoji od natrijevog benzoata, kalijevog benzoata, kalcijevog benzoata i litijevog benzoata i pri čemu je količina benzojeve kiseline ili soli benzojeve kiseline dovoljna za ublažavanje jednog ili više spomenutih simptoma i varira od približno 5 mg do približno 500g.
A siliconized container means filled with a formulation which inhibits silicone induced aggregation of a polysaccharide- protein conjugate comprised in a siliconized container means, the formulation comprising (i) a pH buffered saline solution, wherein the buffer has a pKa of about 3.5 to about 7.5, (ii) an aluminum salt and (iii) one or more polysaccharide-protein conjugates wherein the polysaccharide-protein conjugate comprises one or more pneumococcal polysaccharides. 
HR P20190198 T1 PATENTNI ZAHTJEVI Silikonizirani spremnik napunjen formulacijom koja inhibira silikonom izazvano agregiranje polisaharidno-proteinskog konjugata koji se nalazi u silikoniziranom spremniku, naznačen time što formulacija koja sadrži (i) PH puferiranu fiziološku otopinu, gdje pufer ima pKa od otprilike 3,5 do otprilike 7,5, (ii) aluminijevu sol i (iii) jedan ili više polisaharidno-proteinski konjugati, gdje polisaharidno-proteinski konjugat sadrži jedan ili više pneumokoknih polisaharida.
The heat engine of claim 10, wherein the closed-loop path further comprises at least one heat-transfer conduit external to the heat engine. 
Toplinski motor prema Zahtjevu 9, gdje putanja koja je u znatnoj mjeri u obliku zatvorene petlje dalje sadrži najmanje jedan vod za prenošenje topline koji je eksterni za toplinski motor.
The present disclosure further relates to the nucleic acid previously described which is DNA, cDNA, PNA, CNA, RNA or combinations thereof. The present disclosure further relates to an expression vector capable of expressing a nucleic acid previously described. The present disclosure further relates to a peptide as described before, a nucleic acid as described before or an expression vector as described before for use in medicine. 
Nukleinska kiselina, kodirana za peptid za uporabu s bilo kojim od patentnih zahtjeva od 1 do 4, uz uvjet da peptid nije potpuno humani protein, pri čemu je navedena nukleinska kiselina po mogućnosti DNK, cDNK, PNK, RNK ili kombinacija navedenih, ili ekspresijski vektor koji eksprimira navedenu nukleinsku kiselinu. Nukleinska kiselina ili ekspresijski vektor u skladu s patentnim zahtjevom 5 za uporabu u medicini.
The solvent is typically a water based solvent in order to avoid a frequent and repeated exposure of the nails and the adjacent skin to aggressive organic solvents. 
HR P20070431 T3 Otapalo je obično otapalo bazirano na vodi, kako bi se izbjeglo često i ponavljajuće izlaganje noktiju i susjedne kože agresivnim organskim otapalima.
is independently selected from NR2 and O; 
je neovisno odabran od NR2 i O;
The composition of use according to claim 13, wherein the crenolanib or a salt thereof is provided at least one of sequentially or concomitantly, with another chemotherapeutic agent in a newly diagnosed acute myeloid leukemia (AML), to maintain remission, or a relapsed or refractory acute myeloid leukemia (AML). 
Pripravak namijenjen uporabi u skladu s patentnim zahtjevom 13, pri čemu se crenolanib ili njegova sol osigurava barem jednom slijedno ili istodobno s drugim kemoterapijskim agensom u novodijagnosticiranoj akutnoj mijeloičnoj leukemiji (AML), radi održavanja remisije ili relapsirane ili refraktorne akutne mijeloične leukemije (AML).
(m-1) adding water and allowing crystallisation of the compound of the Formula X to occur, collecting the compound of the Formula X and washing the compound of the Formula X with water, followed by a solvent selected from ethyl acetate, butyl acetate and acetonitrile at a temperature in the range of from 25 to 55° C., conveniently 45 to 55° C.; or 
(m-1) dodavanja vode i dozvoljavanja kristalizacije spoja sa formulom X, i sakupljanja spoja sa formulom X i 15 pranja spoja formule X sa vodom, te nakon toga sa otapalom izabranim između otil acetata, butil acetata i acetonitrila na temperaturi u rasponu od 25 do 55?
An anti IL-1B antibody or binding fragment thereof for use of any of claims 1-9, wherein an initial dose of the anti-IL-1B antibody or binding fragment thereof is administered followed by administration of one or more subsequent doses and wherein the administration of the initial dose and each of one or more subsequent doses are separated from each other by an interval of at least two weeks. 
Anti-IL-1B protutijelo ili njegov IL-1B-vezujući fragment za uporabu prema zahtjevima 1-5, gdje nakon primjene početne doze protutijela ili fragmenta protutijela slijedi primjena jedne ili više sljedećih doza, i gdje je ta jedna ili više sljedećih doza u količini koja je otprilike jednaka ili manja od početne doze.
The aqueous formulation of any of the foregoing claims comprising 90 µg/mL zinc, 2.7 mg/mL m-cresol and 20 mg/mL glycerol 85%. 
Vodena formulacija prema zahtjevu 8 naznačena time da sadrži 90 µg/mL cinka, 2.7 mg/mL m-krezola i 20 mg/mL glicerola 85%.
Furthermore, the location of at least one partially detachable section on the periphery of said first zone reduces the fragilization of the rest of the packaging and also makes it possible to maintain the strength of the packaging even after tearing of said incision lines, owing to lateral maintenance preserved around the containers. 
Ambalažno pakiranje (1) u skladu s bilo kojim od prethodnih zahtjeva, naznačeno time da navedena rezna linija na periferiji navedene središnje zone navedene prve zone (3) sadrži početni dio za olakšavanje započinjanja navedene djelomično odvojive sekcije (4) ambalažnog pakiranja, na primjer gušći rez, otvor ili jezičac.
Saturated to unsaturated fatty acid ratio is modified from 0.6 in normal pig chow to 1.12 in the SFA-CHO diet. 
Odnos zasićenih i nezasićenih masnih kiselina je promijenjen sa 0.6 u normalnoj svinjskoj hrani, do 1.12 u SFA-CHO dijeti.
The compound of any of claims 1-89 that is 3-[5-amino-4-(3-cyanobenzoyl)-pyrazo1-1-yl]-N-cyclopropyl-4-methylbenzamide. A pharmaceutical composition, comprising a compound of any one of claims 1-105 and a pharmaceutically acceptable carrier. 
Spoj formule I, naznačen time, da je to spoj 3-[5-amino-4-(3-cijanobenzoil)-pirazol-1-i1]-N-ciklopropil-4-metil-benzamid, ili njegov farmaceutski prihvatljiv derivat određen u zahtjevu 1, te da je za uporabu prema zahtjevu 1.
The method of claim 28, wherein the anti-viral agent is peramivir. 
Spoj za uporabu sukladno zahtjevu 18, pri čemu je dodatno antivirusno sredstvo peramivir.
Speed by volume of the fluidization air was kept at 60 m3/hour in the first 15 minutes of the pelletization and later at 90 m3/hour. 
Volumna brzina zraka za fluidiziranje održavana je na 60 mVsat tijekom prvih 15 minuta granuliranja i nakon toga na 90 mVsat.
A compound, pharmaceutically acceptable salt, or pharmaceutical composition for use according to claim 5, wherein the disease or medical condition is Alzheimer's Disease, Parkinson's Disease, fronto-temporal Dementia, Dementia with Lewy Bodies (Lewy body disease), Parkinson's Disease with Dementia, Multiple System Atrophy, Amyotrophic Lateral Sclerosis, or Huntington's Disease. 
Spoj, farmaceutski prihvatljiva sol, ili farmaceutska kompozicija za primjenu u skladu sa patentnim zahtjevom 5, gdje je bolest ili medicinsko stanje Alzheimerova bolest, Parkinsonova bolest, fronto-temporalna demencija, demencija sa Levijevim tijelima (bolest Levijevih tijela), Parkinsonova bolest sa demencijom, multipla sistemska atrofija, amiotrofična lateralna skleroza, ili Huntingtonova bolest.
More particularly it relates to compositions and formulations of ecteinascidins, such as ecteinascidin 743. 
Posebno se odnosi na smjese i oblike ekteinascidina, kao što je ekteinascidin
In an embodiment of the present invention, the coating materials can, for example, have a pigment volume concentration from 40 to 80%, for example, from 50 to 70%, or, for example, from 55 to 65%. 
Obložni materijal prema zahtjevu I, naznačen time, da vezivna komponenta ima volumensku koncentraciju pigmenta od 40 do 80%, poželjno od 50 do 70%, posebno poželjno od 55 do 65%.
A composition according to any one of the preceding embodiments, wherein said composition is in the form of a tablet. 
Kompozicija prema prethodnom patentnom zahtjevu, naznačena time što je navedena kompozicija u obliku tablete.
The compound for use according to any one of claims 1 to 4, wherein the eye disease is selected from the group comprising diabetic retinopathy, corneal edema, anterior and posterior uveitis, pterygium, corneal diseases, dry eye, conjunctivitis, allergy- and laser-induced exudation, non-age related macular degeneration, macular edema, age-related macular degeneration and ocular von Hippel-Lindau disease. 
za uporabu u liječenju bolesti oka povezane s upalom i/ili vaskularnom proliferacijom u subjektu; naznačen time što je bolest oka odabrana iz skupine koja sadrži dijabetsku retinopatiju, edem rožnice, prednji i stražnji uveitis, pterigij, bolesti rožnice, suho oko, konjunktivitis, izlučivanje uzrokovano alergijom i laserom, makularnu degeneraciju nepovezanu s dobi, makularni edem, makularnu degeneraciju povezanu s dobi i očnu von Hippel-Lindau bolest.
The solid form of claim 30, wherein the solid form is Form A crystal form characterized by an XRPD pattern comprising peaks at approximately 15.09, 15.94, and 22.30 degrees 2θ. 
(1-5), naznačen time što je čvrsti oblik kristalni oblik Oblika A s karakterističnim XRPD uzorkom koji ima vrhove na približno 15.09, 15.94 i 22.30 stupnjeva 20.
second hinging means (73) ensure, by means of tilting arms (78), an indirect connection of the other end zone of the bars, or alternatively of the other of the parallel sides of the at least one polygonal plate, to second members (45A) of the load bearing structure. 
- druga šarka (73) osigurava, uz pomoć nagibnih krakova (78), posrednu vezu drugog krajnjeg dijela štapova, ili pak druge od paralelnih strana najmanje jedne poligonalne ploče, s drugim elementima (45A) nosive strukture.
Process according to claim 10, wherein the aqueous solution comprises dissolved calcium nitrate and at least a different dissolved nitrate salt, and the setting accelerator having a water content higher than 5% and lower than 20%. 
Postupak u skladu s patentnim zahtjevom 10, naznačen time, da vodena otopina sadržava otopljeni kalcij nitrat i barem jednu drugačiju otopljenu nitratnu sol te akcelerator vezivanja koji ima udjel vode veći od 5 % i manji od
The most preferred form of IL-2 has the 132-mer amino acid sequence shown in Figure 2 (SEQ ID NO: 1), as found in PROLEUKIN™. Compositions are preferably free from IL-2 that does not have N-terminal Ala. 
Najviše preferirani oblik IL-2 ima 132-mernu aminokiselinsku sekvencu prikazanu na Slici 2 (SEQ ID NO: 1), kako je pronađeno u PROLEUKIN- uTM, Sastavi su pogodno slobodni oblik od IL-2 koji nema N-terminalni Ala.
is an unsubstituted phenyl, or a stereoisomer of the compound. 
R5 je nesupstituirani fenil, ili stereoizomer toga spoja.
wherein these noses extend through adapted openings in the metallic lid part; and wherein the collar part and the lid receiving part are connected to the metallic lid part in a shape-matched and force-transmitting manner as well as sealingly by a rivet-like deformation of the noses under the effect of heat while interposing an adhesive promoting layer. 
te time, da su obodni dio (5) i prihvatni dio (10) poklopca odgovarajuće spojeni s metalnim dijelom poklopca tako, da pristaju oblikom i prenose silu, kao i brtveno pomoću deformacija izbočina (30) nalik na zakovice, pod učinkom zagrijavanja za vrijeme umetanja pomoćnog ljepljivog sloja (37).
Aspect 27. The elongate wick of aspect 25 wherein the polymeric material is a thermoplastic polymer. 
Izduženi fitilj (30) prema zahtjevu 22 pri čemu je polimerni materijal termoplastični polimer.
The compound of claim 1, wherein R2 and R5 are not joined together to form a substituted or unsubstituted heterocycloalkyl or substituted or unsubstituted heteroaryl. 
Spoj prema zahtjevu 1, naznačen time što R2 i R5 nisu spojeni da formiraju supstituirani ili nesupstituirani heterocikloalkil ili supstituirani ili nesupstituirani heteroaril.
A method of drilling a hole in the ground using a fluid operated hammer drill having a drill bit with a bit face, the method comprising: 
Postupak za bušenje rupe u zemlji uz korištenje tekućinom pogonjenog čekića bušilice s tekućinom (12) koji ima svrdlo (38) s površinom dlijeta (20), pri čemu postupak sadrži:
A system as set forth in Claim 1, characterized in that said projection (7) is provided on all the key followers (5) of the lock. 
Sustav prema patentnom zahtjevu 1., naznačen time, da se navedeno izbočenje (7) nalazi na svim pomičnim elementima (5) brave.
The recoil damper system described in the aforementioned application provides for an end plate, to be secured to a rifle stock, comprising a hydraulic damper placed between two sliding guides in the form of bushes fitted with linear roller bearings. 
Sustav prigušivanja trzanja, koji je opisan u prije spomenutoj prijavi, predviđa jednu krajnju ploču koja je pričvršćena na kundak puške i koja sadržava hidraulički prigušivač koji je smješten između dvije klizne vodilice u obliku čahura koje su opremljene s linearnim valjkastim ležajevima.